Matthew Roden has served as Aktis Oncology's President and Chief Executive Officer and as a member of its board of directors since September 2020. Since August 2020 he has also worked as an Entrepreneur Partner at MPM BioImpact, a biotechnology investment firm, and previously served as Senior Vice President and Head of Enterprise Strategy at Bristol Myers Squibb after leading its strategic corporate development and business development functions. Earlier in his career he was an equity research analyst at UBS Investment Bank and J.P. Morgan, and he holds a PhD in Microbiology and Immunology from the Albert Einstein College of Medicine.